journal: Advances in Laboratory Medicine / Avances en Medicina de Laboratorio

Impact Factor: 1.0

Open Access Published since February 20, 2020

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio

Official Journal of the Spanish Society of Laboratory Medicine SEQC-ML

ISSN: 2628-491X

Editor-in-chief: Álvaro González Hernández

Edited by: Pilar Fernandez Calle, Ignacio Arribas Gómez, Wladimiro Jiménez Povedano

Submit manuscript

About this journal

Objective: Advances in Laboratory Medicine / Avances en Medicina de Laboratorio (Adv Lab Med) is the official journal of the Spanish Society of Laboratory Medicine (SEQC^ML). Adv Lab Med publishes contributions in the field of medical sciences, including Biochemistry, Hematology, Toxicology, Microbiology and Parasitology, Immunology, and Genetics. Articles focusing on the choice, performance or interpretation of clinical tests are especially welcome.
Adv Lab Med publishes quarterly. All contributions submitted for publication in Adv Lab Med are single-blind peer reviewed by at least two experts in the field, selected and invited by the Editor-in-Chief. Adv Lab Med is an Open Access journal with an international board of renowned editors. Authors are not charged for manuscript processing and Open Access publication. SEQC^ML covers processing and publication charges. The Society plays no role in the selection and publication of the articles, nor does it influence peer review. Adv Lab Med is a bilingual journal, and all articles are published in both English and Spanish.

Please submit your manuscript here

Submissions in the following fields are welcome:

Clinical Chemistry
Clinical Hematology and Coagulation
Genetic and Molecular Biology
Clinical Immunology and Autoimmunity
Clinical Microbiology and Parasitology
Drug Monitoring and Toxicology
Evaluation of Diagnostic Biomarkers
New Technologies and Methodologies
Reference Materials and Methods
Reference Values and Decision Limits
Quality Control
Translational Laboratory Medicine
Endocrinology and Metabolism
Lipids and Lipoproteins
Cardiovascular Risk Factors
Cancer Biomarkers
Clinical Metrology
Laboratory Management
POCT

Article Formats

Research Articles: full length articles and short communications
Reviews and Mini Reviews
Opinion Papers
Editorials
Letters to the Editor and Replies
Case Reports
Guidelines and Recommendations

Your Benefits

Latest developments in the clinical laboratory sciences
Fundamental and applied approach
Novel teaching and training methods
High quality peer-review
No Article Processing Charge
Publication under the Creative Commons Attribution (CC-BY-4.0) License
Free translation of each article into Spanish or English

History

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio was founded by the Spanish Society of Laboratory Medicine (SEQC^ML), and launched at EuroMedLab 2019 in Barcelona.

Other publications in the field

Abstracting and Indexing

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio is covered by the following services:

Baidu Scholar
Chronos Hub
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO Discovery Service
Google Scholar
J-Gate
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
PubMed
PubMed Central
ReadCube
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Summon (ProQuest)
TDNet
WanFang Data
Web of Science - Emerging Sources Citation Index
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

Topics

External Links

Volume 4 Issue 2

June 2023

Publicly Available June 22, 2023

Frontmatter

Page range: i-ii

Download PDF

Editorial

Open Access May 31, 2023

Quo vadis, LDL cholesterol?

Andrés Cobos, Pedro Valdivielso

Page range: 133-134

Download PDF

Open Access May 30, 2023

Quo vadis, colesterol de las LDL?

Andrés Cobos, Pedro Valdivielso

Page range: 135-137

Download PDF

Guidelines and Recommendations / Guias y Recomendaciones

Open Access June 5, 2023

Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?

Teresa Arrobas Velilla, Carlos Guijarro, Raquel Campuzano Ruiz, Manuel Rodríguez Piñero, José Francisco Valderrama Marcos, Antonio Pérez Pérez, Antonio M. Botana López, Ana Morais López, José Antonio García Donaire, Juan Carlos Obaya, Luis Castilla Guerra, Vicente Pallares Carratalá, Isabel Egocheaga Cabello, Mercedes Salgueira Lazo, María Mar Castellanos Rodrigo, José María Mostaza Prieto, Juan José Gómez Doblas, Antonio Buño Soto, on behalf of the Multidisciplinary Task Force for Lipids and Vascular Risk

Page range: 138-146

More Download PDF

Abstract

Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports.

Open Access May 18, 2023

Documento de consenso para la determinación e informe del perfil lipídico en laboratorios clínicos españoles: ¿Qué parámetros debe incluir un perfil lipídico básico?

Teresa Arrobas Velilla, Carlos Guijarro, Raquel Campuzano Ruiz, Manuel Rodríguez Piñero, José Francisco Valderrama Marcos, Antonio Pérez Pérez, Manuel Antonio Botana López, Ana Morais López, José Antonio García Donaire, Juan Carlos Obaya, Luis Castilla Guerra, Vicente Pallares Carratalá, Isabel Egocheaga Cabello, Mercedes Salgueira Lazo, María Mar Castellanos Rodrigo, José María Mostaza Prieto, Juan José Gómez Doblas, Antonio Buño Soto, en representación del Grupo Multidisciplinar de Trabajo de Lípidos y Riesgo Vascular

Page range: 147-156

More Download PDF

Abstract

Resumen Las enfermedades cardiovasculares (ECV) siguen siendo la principal causa de muerte en nuestro país. El control adecuado de las alteraciones del metabolismo lipídico es un reto clave en prevención cardiovascular que está lejos de alcanzarse en la práctica clínica real. Existe una gran heterogeneidad en los informes del metabolismo lipídico de los laboratorios clínicos españoles, lo que puede contribuir al mal control del mismo. Por ello, un grupo de trabajo de las principales sociedades científicas implicadas en la atención de los pacientes de riesgo vascular hemos elaborado este documento con una propuesta básica de consenso sobre la determinación del perfil lipídico básico en prevención cardiovascular, recomendaciones para su realización y unificación de criterios para incorporar los objetivos de control lipídico adecuados al riesgo vascular de los pacientes en los informes de laboratorio.

Original Article / Artículo Original

Open Access April 11, 2023

Testing the stability of internal quality controls stored in the automated Atellica Solution refrigerated storage module

Patricia Rayo Hidalga, Carlos Domingo Bautista, Rosa Fernandez Bonifacio, Jose L. Bedini Chesa, Naira Rico Santana

Page range: 157-165

More Download PDF

Abstract

Objectives Atellica Solution (AS) is a platform that incorporates immunoassay and chemistry modules. AS is fitted with a refrigerated storage module (RSM) for internal quality controls (QC). The objective of this study was to assess the maximum permissible storage time in AS for QCs. Methods A total of 48 analytes were tested using QC materials: Liquid Assayed Multiqual (MQ), Liquichek Immunology (LI), Liquichek Lipids (LL), and Liquichek Urine Chemistry (UC). The percentage of variation between results (Xt%) was calculated as the difference between the mean value of the triplicate performed at every time point of the study (Xt) and the average of the triplicate performed in the baseline time (Xo). Stability was assessed based on the total change limit (TCL), which combines analytical and biological variation: TCL=±√((1.65 * CVa) 2 + (0.5 * CVb) 2 ). Results A total of 40 of the 48 analytes tested remained stable at the end of the study. In relation to MQ and UC QCs, 32 of the 39 analytes remained stable for the whole study period (15 days) except for alkaline phosphatase, aspartate aminotransferase, calcium, lactate dehydrogenase, and total bilirubin in MQ, and chlorine and glucose in UC. In LI and LL QCs, eight of the nine analytes were stable throughout the 20 days of the study, except transferrin in LI. Conclusions The Atellica Solution refrigerated storage module is a reliable system for the storage of quality control materials.

Open Access February 20, 2023

Estudio de estabilidad de los controles de calidad internos almacenados en el módulo de refrigeración automatizado de Atellica Solution

Patricia Rayo Hidalga, Carlos Domingo Bautista, Rosa Fernández Bonifacio, José Luis Bedini, Naira Rico

Page range: 166-174

More Download PDF

Abstract

Resumen Objetivos Atellica Solution (AS) es una plataforma que permite incorporar módulos de bioquímica e inmunoanálisis y almacenar controles de calidad internos (CC) en su interior gracias al módulo de refrigeración (MR). El objetivo del estudio es analizar el tiempo máximo de estabilidad de los CC almacenados en su interior. Métodos Se analizaron 48 magnitudes mediante materiales CC: Liquid Assayed Multiqual (MQ), Liquichek Immunology (LI), Liquichek Lipids (LL), y Liquichek Urine Chemistry (UC). La variación en los resultados (Xt %) se calculó comparando el promedio del análisis realizado en cada momento (Xt) con el promedio realizado en el momento inicial del estudio (Xo), y se expresó como un cambio porcentual: (Xt%) = (Xt/Xo) × 100. La estabilidad se evaluó de acuerdo con el límite de cambio total (LCT) el cual combina la variabilidad analítica y biológica: LCT = ±√((1,65 × CVa) 2 + (0,5 × CVb) 2 ) Resultados Un total de 40 de las 48 magnitudes estudiadas fueron estables al finalizar el estudio. En el caso del CC MQ y el UC 32 de las 39 magnitudes fueron estables durante los 15 días del estudio, excepto fosfatasa alcalina, aspartato aminotransferasa, calcio, lactato deshidrogenasa y bilirrubina total en MQ y cloro y glucosa en UC. En los CC LI, LL 8 de las 9 magnitudes fueron estables durante los 20 días del estudio, a excepción de la transferrina en LI. Conclusiones El módulo de refrigeración de Atellica Solution es un sistema fiable para mantener almacenados los materiales de control de calidad.

Open Access March 24, 2023

Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection?

Giuseppe Lippi, Brandon M. Henry, Laura Pighi, Simone De Nitto, Gian Luca Salvagno

Page range: 175-179

More Download PDF

Abstract

Objectives We planned this study to verify whether immunoassays for quantifying anti-SARS-CoV-2 IgG/IgM antibodies against both spike (S) and nucleocapsid (N) proteins may be used for identifying previous SARS-CoV-2 infections. Methods The study population consisted of a cohort of fully vaccinated healthcare workers. All study subjects underwent regular medical visits and molecular testing for diagnosing SARS-CoV-2 infections every 2–4 weeks between 2020–2022. Venous blood was drawn for measuring anti-SARS-CoV-2 antibodies with MAGLUMI 2019-nCoV lgG/IgM CLIA Assays directed against both SARS-CoV-2 S and N proteins. Results Overall, 31/53 (58.5%) subjects had tested positive for SARS-CoV-2 by RT-PCR throughout the study (24 once, 7 twice). No positive correlation was found between anti-SARS-CoV-2 S/N IgM antibodies and molecular test positivity. In univariate regression analysis, both a molecular test positivity (r=0.33; p=0.015) and the number of positive molecular tests (r=0.43; p=0.001), but not vaccine doses (r=−0.12; p=0.392), were significantly correlated with anti-SARS-CoV-2 S/N IgG antibodies. These two associations remained significant in multiple linear regression analysis (p=0.029 and p<0.001, respectively) after adjusting for sex, age, body mass index, and vaccine doses. In ROC curve analysis, anti-SARS-CoV-2 S/N IgG antibodies significantly predicted molecular test positivity (AUC, 0.69; 95% CI; 0.55–0.84), with the best cutoff of 0.05 AU/mL displaying 67.9% accuracy, 0.97 sensitivity, and 0.27 specificity. Conclusions Although anti-SARS-CoV-2 S/N IgG antibodies provide helpful information for identifying previous SARS-CoV-2 infections, a lower cutoff than that of sample reactivity should be used. Anti-SARS-CoV-2 S/N IgM antibodies using conventional cutoffs seem useless for this purpose.

Open Access May 5, 2023

¿Son los anticuerpos IgG e IgM contra los antígenos S y N del SARS-CoV-2 siempre predictores de infección previa por SARS-CoV-2?

Giuseppe Lippi, Brandon M. Henry, Laura Pighi, Simone De Nitto, Gian Luca Salvagno

Page range: 180-184

More Download PDF

Abstract

Resumen Objetivos Evaluamos si los inmunoensayos con anticuerpos IgG e IgM contra las proteínas spike (S) y nucleocápside (N) del SARS-CoV-2 detectan infecciones previas por SARS-CoV-2. Métodos Analizamos una cohorte de profesionales sanitarios que había completado el ciclo de vacunación. Desde 2020, y cada 2–4 semanas, se les realizaron revisiones médicas y pruebas moleculares para diagnosticar una posible infección por SARS-CoV-2. Se extrajeron muestras de sangre venosa para medir los niveles de anticuerpos contra el SARS-CoV-2 con los ensayos MAGLUMI ® 2019-nCoV lgG y 2019-nCoV lgM CLIA dirigidos a las proteínas S y N del SARS-CoV-2. Resultados En total, la prueba RT-PCR fue positiva para SARS-CoV-2 en 31 (58,5 %) sujetos (el resultado fue positivo una vez en 24 sujetos y dos veces en 7). No se observó una relación directa entre los niveles de anticuerpos IgM contra S y N del SARS-CoV-2 y la positividad de la prueba molecular. El análisis de regresión univariante reveló una relación estadísticamente significativa entre los anticuerpos IgG contra S y N del SARS-CoV-2 y una prueba molecular positiva (r=0,33; p=0,015) y el número de pruebas moleculares positivas (r=0,43; p=0,001). Sin embargo, no se observó correlación con el número de dosis de la vacuna (r=−0,12; p=0,392). La significación se mantuvo en el análisis de regresión lineal (p=0,029 y p<0,001, respectivamente) tras controlar el efecto del sexo, edad, índice de masa corporal y dosis de la vacuna. En el análisis de la curva ROC, los IgG contra S y N del SARS-CoV-2 predijeron significativamente la positividad de la prueba molecular (AUC, 0,69; IC95 %; 0,55–0,84). El mejor valor umbral fue 0,05 AU/mL, con una precisión del 67,9 %, una sensibilidad del 0,97, y una especifidad de 0,27. Conclusiones Aunque los anticuerpos IgG contra S y N del SARS-CoV-2 proporcionan información útil para identificar infecciones previas por SARS-CoV-2, se debería emplear un valor umbral inferior al de la reactividad de la muestra. Los anticuerpos IgM contra S y N del SARS-CoV-2 no son válidos para tal fin.

Case Report / Caso Clínico

Open Access March 6, 2023

No increase in the CTG repeat size during transmission from parent with expanded allele: false suspicion of contraction phenomenon

Nuria Goñi Ros, Paula Sienes Bailo, Ricardo González Tarancón, Loreto Martorell Sampol, Silvia Izquierdo Álvarez

Page range: 185-189

More Download PDF

Abstract

Objectives Myotonic dystrophy type 1 (DM1), also known as Steinert’s disease, is a chronic, progressive and disabling multisystemic disorder with a broad spectrum of severity that arises from an autosomal-dominant expansion of the Cytosine-Thymine-Guanine (CTG) triplet repeat in the 3′ untranslated region of the DMPK gene (19q13.3). Case presentation In this study, we report the case of a family with several intergenerational expansions of the CTG repeat, with an additional case of a false suspicion of contraction phenomenon due to TP-PCR limitations. Conclusions The meiotic instability of the (CTG) n repeats leads to genetic anticipation where increased size of DM1 mutation and a more severe phenotype have been reported in affected individuals across generations. Even if extremely rare, a decrease in the CTG repeat size during transmission from parents to child can also occur, most frequently during paternal transmissions.

Open Access March 2, 2023

Tamaño de repeticiones CTG no aumentado en la transmisión de un padre con alelo expandido: falsa sospecha de fenómeno de contracción

Nuria Goñi Ros, Paula Sienes Bailo, Ricardo González Tarancón, Loreto Martorell Sampol, Silvia Izquierdo Álvarez

Page range: 190-194

More Download PDF

Abstract

Resumen Objetivos La distrofia miotónica tipo 1, conocida también como enfermedad de Steinert, es un desorden multisistémico crónico, degenerativo e incapacitante de expresividad clínica muy variable provocado por una expansión heredada de manera autosómica dominante de la repetición del triplete citosina-timina-guanina, localizada en la región 3′ no codificante del gen DMPK (19q13.3). Caso clínico En este estudio, presentamos el caso de una familia con varias expansiones de la repetición CTG intergeneracionales, con un caso adicional de falsa sospecha de fenómeno de contracción, debido a las limitaciones de la técnica TP-PCR. Conclusiones La inestabilidad meiótica de las repeticiones de (CTG) n provoca anticipación genética. De este modo, a lo largo de las sucesivas generaciones, se ha hallado un incremento del tamaño de la mutación DM1 y un fenotipo más severo en los individuos afectados. Aunque es extremadamente infrecuente, en la transmisión de padres a hijos, también puede producirse una disminución en el número de repeticiones CTG, siendo esta más frecuente en la transmisión paterna.

Open Access March 15, 2023

Patient with adrenal insufficiency due to a de novo mutation in the NR0B1 gene

Daniel Bravo Nieto, Alba S. García Fernández, Noelia Díaz Troyano, Marina Giralt Arnaiz, Andrea Arias García, Paula Fernández Álvarez, Ariadna Campos Martorell, Roser Ferrer Costa, María Clemente León

Page range: 195-198

More Download PDF

Abstract

Objectives Congenital X-linked adrenal hypoplasia is a rare disease with a known genetic basis characterized by adrenal insufficiency, hypogonadotropic hypogonadism, and a wide variety of clinical manifestations. Case presentation We present the case of a 26-day old male newborn with symptoms consistent with adrenal insufficiency, hyponatremia, and hyperkalemia. Following NaCl and fludrocortisone supplementation, the patient remained clinically stable. 17-OH-progesterone testing excluded congenital adrenal hyperplasia. The rest of hormones were within normal limits, except for adrenocorticotropic hormone (ACTH), which was significantly elevated, and aldosterone, which was below the reference value. Further testing included very long chain fatty acids to exclude adrenoleukodystrophy, the CYP11B2 gene (aldosterone synthase), and an MRI to screen for other morphological abnormalities. All tests yielded normal results. Finally, after cortisol deficiency was detected, expanded genetic testing revealed a mutation in the NR0B1 gene, which led to a diagnosis of congenital adrenal hypoplasia. Conclusions Diagnosis of congenital adrenal hypoplasia is challenging due to the heterogeneity of both clinical manifestations and laboratory abnormalities. As a result, diagnosis requires close monitoring and genetic testing.

Open Access March 24, 2023

Paciente con insuficiencia suprarrenal por mutación de novo en el gen NR0B1

Daniel Bravo Nieto, Alba S. García Fernández, Noelia Diaz Troyano, Marina Giralt Arnaiz, Andrea Arias García, Paula Fernández Álvarez, Ariadna Campos Martorell, Roser Ferrer Costa, María Clemente León

Page range: 199-202

More Download PDF

Abstract

Resumen Objetivos La hipoplasia suprarrenal congénita ligada al cromosoma X es una enfermedad rara con base genética conocida, que se presenta con insuficiencia suprarrenal e hipogonadismo hipogonadotrófico y expresión clínica variable. Caso clínico Paciente varón, de 26 días, que ingresó con síntomas compatibles con insuficiencia suprarrenal, hiponatremia e hiperpotasemia, requiriendo sueroterapia con suplementos de NaCl y fludrocortisona, consiguiéndose estabilidad clínica. Se descartó la hiperplasia suprarrenal congénita tras la medición de 17-OH-progesterona. El resto de hormonas estaban dentro de los intervalos de referencia, salvo la hormona adrenocorticotrópica (ACTH), sensiblemente por encima, y la aldosterona, por debajo. En los siguientes análisis se estudiaron los ácidos grasos de cadena muy larga para descartar adrenoleucodistrofia, el gen CYP11B2 (aldosterona sintasa), y se realizó una RMN para descartar otras alteraciones morfológicas. Todas estas pruebas resultaron normales. Finalmente, tras detectar déficit de cortisol en una analítica, se realizó un estudio genético más amplio donde se describió una mutación en el gen NR0B1, estableciéndose el diagnóstico de hipoplasia suprarrenal congénita. Conclusiones La hipoplasia suprarrenal congénita es una enfermedad de diagnóstico complejo debido a la variabilidad en la expresión clínica y el grado de alteración de las pruebas de laboratorio, requiriéndose un seguimiento exhaustivo y la realización de pruebas genéticas para llegar al diagnóstico.

Ahead of Print / Just Accepted

Ahead of Print / Just Accepted

Volume 4 (2023)

Volume 3 (2022)

Volume 2 (2021)

Volume 1 (2020)

Journal Impact Factor	1.0	2022, Journal Citation Reports (Clarivate, 2023)
5-year Journal Impact Factor	1.0	2022, Journal Citation Reports (Clarivate, 2023)
Journal Citation Indicator	0.19	2022, Journal Citation Reports (Clarivate, 2023)
CiteScore	0.7	2022, Scopus (Elsevier B.V., 2023)
SCImago Journal Rank	0.199	2022, SJR (Scimago Lab, 2023; Data Source: Scopus)
Source Normalized Impact per Paper	0.281	2022, CWTS Journal Indicators (CWTS B.V., 2023; Data Source: Scopus)

More information about journal rankings

Submit

Submission

You can easily submit your manuscript online. Simply go to http://mc.manuscriptcentral.com/almed and you will be guided through the whole submission and publishing process.

Your benefits of publishing with us

Rapid publication times
No submission fee
No article processing charge (APC)
Open Access - research freely available for all to read and download
Authors retain copyright – articles published under the Creative Commons Attribution (CC-BY-4.0) License
Free translation of each article into Spanish or English funded by unrestricted education grant
Every article easily discoverable because of SEO and comprehensive abstracting and indexing services
Secure archiving by De Gruyter and the independent archiving service Portico

Submission process

Submission of your manuscript via our submission management tool following the Information for Authors
Single-blind peer review process
A decision on your paper is aspired within 3-4 weeks
Accepted articles are published online ahead of print approx. 4 weeks after acceptance

Please note

Manuscripts must be written in clear and concise English or Spanish
Before submitting your article please have a look at the Submission Checklist and Publication Ethics Statement
The License to Publish must be filled in and signed, and submitted as separate file
As a condition of submission, the Template for Ethical and Legal Declarations (ENGLISH or SPANISH) must be customized by the submitting author on behalf of all others and uploaded as a separate Word file. Instructions on how to make declarations can be found here
If you have any general questions please visit our FAQ page for authors
For more detailed information please contact the Editorial Office editorial.office@seqc.es

We look forward to receiving your manuscript!

Editorial

Editor-in-Chief
Álvaro González Hernández, Clínica Universidad de Navarra, Pamplona, Spain
agonzaleh@unav.es

Associate Editors
Ignacio Arribas Gómez, Hospital Universitario Ramón y Cajal, Madrid, Spain
arribasignacio@gmail.com

Pilar Fernández Calle, Hospital La Paz, Madrid, Spain
pfernandez.hulp@gmail.com

Wladimiro Jiménez Povedano, Universitat de Barcelona, Barcelona, Spain
wjimenez@clinic.cat

Advisory Board
Mª Belén Aparicio Hernández, Hospital Universitario de Salamanca, Salamanca, Spain
salaautoinmunidad@yahoo.es

Hugo Azevedo Rocha, Instituto Nacional de Saude Ricardo Jorge, Porto, Portugal
hugodanielrocha@netcabo.pt

Antonio Buño Soto, Hospital La Paz, Madrid, Spain
antoniobuno@gmail.com

María José Calasanz Abinzano, Universidad de Navarra, Pamblona, Spain
mjcal@unav.es

Francesca Canalias Reverter, Universitat Autònoma de Barcelona, Barcelona, Spain
francesca.canalias@uab.cat

Edgardo Carosella, Hemato-Immunology Research Department, CEA, Hospital Saint Louis, Paris, France
edgardo.carosella@cea.fr

Patrocinio Chueca Rodríguez, SEQC-ML, Comite de Comunicacion, Navarra, Spain
patrochueca@gmail.com

Abdurrahman Coskun, Ali Aydinlar University, Istanbul, Turkey
coskun2002@gmail.com

Ana Belén Crujeiras, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain
anabelencrujeiras@hotmail.com

Amitava Dasgupta, University of Texas McGovern Medical School at Houston and Laboratory Services, Memorial-Hermann Hospital at Texas Medical Center, Houston, TX, USA
Amitava.Dasgupta@uth.tmc.edu

Ángel Díaz Lagares, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) CIBERONC, Santiago de Compostela, Spain
adiazla@gmail.com

Miguel Fernández de Sanmamed Gutiérrez, Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
msanmamed@unav.es

Maurizio Ferrari, Vita-Salute San Raffaele University, Milan, Italy
ferrari.maurizio@hsr.it

Xavier Filella Pla, Hospital Clínic, Barcelona, Spain
xfilella@clinic.cat

Callum G. Fraser, University of Dundee, Dundee Scotland, UK
callum.fraser@nhs.net

Rubén Gómez Rioja, Hospital La Paz, Madrid, Spain
rgrioja@salud.madrid.org

Montserrat González Estecha, Hospital Clínico San Carlos, Madrid, Spain
MONTSE@CMPX.NET

Damien Gruson, Cliniques universitaires Saint-Luc, Brussels, Belgium
damien.gruson@uclouvain.be

Eva Guillén Campuzano, President of the Scientific Committee of SEQC^ML, Barcelona, Spain
eguillen@catlab.cat

Joao Tiago Guimaraes, University of Porto, Porto, Portugal
jtguimar@med.up.pt

Anatoli Horuzsko, Georgia Cancer Center at Augusta University, Augusta, GA, USA
ahoruzsko@augusta.edu

Mercè Ibarz Escuer, Hospital U. Arnau de Vilanova, Lleida, Spain
mibarz.lleida.ics@gencat.cat

Eric S. Kilpatrick, Sidra Medical and Research Center, Doha, Qatar
kilpatricks@cshs.org

Giuseppe Lippi, University Hospital of Verona, Verona, Italy
giuseppe.lippi@univr.it

Eva Martínez Cáceres, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
emmartinez.germanstrias@gencat.cat

Anna Merino González, Hospital Clínic, Barcelona, Spain
amerino@clinic.ub.es

Manuel Morales Ruiz, Hospital Clínic. Barcelona, Barcelona, Spain
morales@clinic.cat

Miguel Angel Moreno Pelayo, Hospital Universitario Ramón y Cajal, Madrid, Spain
mmorenop@salud.madrid.org

Michael Neumaier, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany
michael.neumaier@medma.uni-heidelberg.de

Josep Oriola Ambrós, Hospital Clínic, Barcelona, Spain
joriola@clinic.ub.es

Alberto Pérez-Mediavilla, Universisad de Navarra, Pamplona, Spain
lamediav@unav.es

Mario Plebani, University Hospital Padova, Padova, Italy
mario.plebani@unipd.it

Belén Prieto García, Hospital Universitario Central de Asturias, Oviedo, Spain
prietobelen7@gmail.com

Jose Puzo Foncillas, Hospital General San Jorge, Huesca, Spain
JPUZO@UNIZAR.ES

Rodolfo Alberto Rey, University of Buenos Aires, Buenos Aires, Argentina
rodolforey@cedie.org.ar

Carmen Ricós Águila, Quality Commission, SEQC^ML, Barcelona, Spain
cricosaguila@gmail.com

Francisco Rodriguez Frias, Hospital Vall d'Hebron, Barcelona, Spain
frarodriguez@vhebron.net

Sverre Sandberg, Haukeland University Hospital, Bergen, Norway
sverre.sandberg@noklus.no

Ana-Maria Šimundić, Clinical Hospital Sveti Duh Zagreb, Zagreb, Croatia
am.simundic@gmail.com

Christos Tsatsanis, University of Crete Medical School, Heraklion, Greece
tsatsani@uoc.gr

Rafael Venta Obaya, Hospital San Agustín, Asturias, Spain
rafael.venta@sespa.es

Franz Villarroel Espindola, Fundación Arturo López Pérez, Providencia, Chile
franz.villarroel@falp.org

Ian Young, Queen’s University Belfast, Belfast, UK
i.young@qub.ac.uk

Inès Zidi, University of Tunis El Manar, Tunis, Tunisia
ines.zidi@istmt.utm.tn

Managing Editors
Roser Ferrer Costa, Hospital Universitari Vall d'Hebron, Barcelona, Spain
roser.ferrer@vallhebron.cat

Albert Bastias González, Barcelona, Spain
editorial.office@seqc.es

Editorial Office
Heike Jahnke
De Gruyter
Genthiner Str. 13
10785 Berlin
Germany
E-mail: Heike.Jahnke@degruyter.com

(Deutsch)

Type: Journal
Languages: English, Spanish
Publisher: De Gruyter
First published: February 20, 2020
Publication Frequency: 4 Issues per Year
Audience: basic scientists, translational researchers, clinical researchers, industry scientists and professionals in the field of laboratory medicine